About Aspartyl/asparaginyl beta-hydroxylase
Aspartyl/asparaginyl beta-hydroxylase (ASPH) is a protein
from Homo sapiens identified by UniProt accession
Q12797, 758 residues long.
MolForge cross-references it against 0 known binders and
377 disease associations.
Target properties
| Protein name | Aspartyl/asparaginyl beta-hydroxylase |
|---|
| UniProt accession | Q12797 |
|---|
| Gene | ASPH |
|---|
| Organism | Homo sapiens |
|---|
| Length | 758 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (11)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (377)
Diseases linked to this target (Open Targets).
- facial dysmorphism-lens dislocation-anterior segment abnormalities-spontaneous filtering blebs syndrome · score 0.76
- blood protein measurement · score 0.42
- malignant hyperthermia of anesthesia · score 0.42
- exercise-induced malignant hyperthermia · score 0.42
- protein measurement · score 0.26
- breast adenocarcinoma · score 0.25
- genetic disorder · score 0.19
- head and neck squamous cell carcinoma · score 0.13
- paralytic strabismus · score 0.12
- endometrial cancer · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q12797-F1 | alphafold | PREDICTED | 71.84 | — |
Amino-acid sequence (758 residues)
MAQRKNAKSS GNSSSSGSGS GSTSAGSSSP GARRETKHGG HKNGRKGGLS GTSFFTWFMV IALLGVWTSV AVVWFDLVDY EEVLGKLGIY DADGDGDFDV DDAKVLLGLK ERSTSEPAVP PEEAEPHTEP EEQVPVEAEP QNIEDEAKEQ IQSLLHEMVH AEHVEGEDLQ QEDGPTGEPQ QEDDEFLMAT DVDDRFETLE PEVSHEETEH SYHVEETVSQ DCNQDMEEMM SEQENPDSSE PVVEDERLHH DTDDVTYQVY EEQAVYEPLE NEGIEITEVT APPEDNPVED SQVIVEEVSI FPVEEQQEVP PETNRKTDDP EQKAKVKKKK PKLLNKFDKT IKAELDAAEK LRKRGKIEEA VNAFKELVRK YPQSPRARYG KAQCEDDLAE KRRSNEVLRG AIETYQEVAS LPDVPADLLK LSLKRRSDRQ QFLGHMRGSL LTLQRLVQLF PNDTSLKNDL GVGYLLIGDN DNAKKVYEEV LSVTPNDGFA KVHYGFILKA QNKIAESIPY LKEGIESGDP GTDDGRFYFH LGDAMQRVGN KEAYKWYELG HKRGHFASVW QRSLYNVNGL KAQPWWTPKE TGYTELVKSL ERNWKLIRDE GLAVMDKAKG LFLPEDENLR EKGDWSQFTL WQQGRRNENA CKGAPKTCTL LEKFPETTGC RRGQIKYSIM HPGTHVWPHT GPTNCRLRMH LGLVIPKEGC KIRCANETKT WEEGKVLIFD DSFEHEVWQD ASSFRLIFIV DVWHPELTPQ QRRSLPAI
Explore Aspartyl/asparaginyl beta-hydroxylase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets